Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93 + GLA-SE Vaccination in Rifampicin-Susceptible Pulmonary TB
NCT06205589Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Oct 2028
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of ID93 + GLA-SE in Tuberculosis (TB). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06205589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205589.